Macrogen, Inc.

Equities

A038290

KR7038290003

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
19,640 KRW +1.92% Intraday chart for Macrogen, Inc. +2.13% -6.48%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Lotte Card Teams Up With Macrogen for Genetic Testing Services MT
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Macrogen, Inc.'s Equity Buyback announced on October 21, 2022, has expired with 138,097 shares, representing 1.37% for KRW 2,825.59 million. CI
Macrogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Macrogen, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares. CI
Macrogen, Inc. authorizes a Buyback Plan. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020. CI
Macrogen, Inc.'s Equity Buyback announced on November 2, 2020, has expired with 168,300 shares, representing 1.72% for KRW 4,957.38 million. CI
Macrogen, Inc.(KOSDAQ:A038290) added to S&P Global BMI Index CI
Macrogen, Inc.(KOSDAQ:A038290) dropped from S&P Global BMI Index CI
Macrogen, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
Macrogen, Inc. authorizes a Buyback Plan. CI
Macrogen Signs Export Agreement with LG International CI
Macrogen, Inc. Obtains Export Approval for COVID-19 Test Kit AxenTM Covid-19 RT CI
Macrogen Approves for Export of Its COVID-19 Test Kit CI
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific CI
Macrogen, Inc.’s Equity Buyback announced on January 11, 2019, has expired. CI
Chart Macrogen, Inc.
More charts
Macrogen, Inc. is a Korea-based company mainly engaged in the customized transgenic and other services in the field of biomedical research. The Company operates its business through four divisions: deoxyribonucleic acid (DNA) sequencing division, DNA chips division, transgenic and knockout mouse division and oligonucleotide DNA division. Its DNA sequencing division provides genome sequencing analysis services. Its DNA chips division develops DNA chips products, such as Illumina chips, MacArray chips and customized chips. Its transgenic and knockout mouse division offers gene engineering services. Its oligonucleotide DNA division offers oligonucleotide DNA manufacturing services. The Company operates its business within domestic market and in overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19,640 KRW
Average target price
27,000 KRW
Spread / Average Target
+37.47%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A038290 Stock
  4. News Macrogen, Inc.
  5. Lotte Card Teams Up With Macrogen for Genetic Testing Services